Faculty
Daniel Morgensztern.jpg

Daniel Morgensztern, MD

Associate Professor
Department of Medicine
Oncology Division
Medical Oncology

Clinical Interests

  • Thoracic malignancies

Research Interests

  • Genomics
  • Immunotherapy
  • Epidemiology
  • Phase 1 and 2 trials

Contact

  • 314-362-5817 (office)
  • 314-362-7086 (fax)
  • 11th Floor Mid-Campus Center (office)
  • Division of Oncology
    Campus Box 8056
    Washington University Medical School
    660 South Euclid Avenue
    St. Louis, MO 63110

Publications

  • Adjuvant chemotherapy is associated with improved survival in locally invasive node negative non-small cell lung cancer
    Ahmad U, Crabtree TD, Patel AP, Morgensztern D, Robinson CG, Krupnick AS, Kreisel D, Jones DR, Patterson GA, Meyers BF, Puri V
    Ann Thorac Surg 2017 Apr 19; [Epub ahead of print]
  • Defining the ideal time interval between planned induction therapy and surgery for stage IIIA non-small cell lung cancer
    Samson P, Crabtree TD, Robinson CG, Morgensztern D, Broderick S, Krupnick AS, Kreisel D, Patterson GA, Meyers B, Puri V
    Ann Thorac Surg 2017 Apr;103(4):1070-1075
  • Precision medicine in lung cancer: the battle continues
    Waqar SN, Morgensztern D
    J Thorac Dis 2016 Nov;8(11):2991-2993
  • Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study
    Rudin CM, Pietanza MC, Bauer TM, Ready N, Morgensztern D, Glisson BS, Byers LA, Johnson ML, Burris HA 3rd, Robert F, Han TH, Bheddah S, Theiss N, Watson S, Mathur D, Vennapusa B, Zayed H, Lally S, Strickland DK, Govindan R, Dylla SJ, Peng SL, Spigel DR
    SCRX16-001 investigators

    Lancet Oncol 2017 Jan;18(1):42-51
  • Evolving treatment options for lung cancer
    Morgensztern D, Herbst RS
    Hematol Oncol Clin North Am 2017 Feb;31(1):xiii-xiv
  • Systemic treatment of brain metastases
    Waqar SN, Morgensztern D, Govindan R
    Hematol Oncol Clin North Am 2017 Feb;31(1):157-176
  • Immunotherapy in lung cancer
    Du L, Herbst RS, Morgensztern D
    Hematol Oncol Clin North Am 2017 Feb;31(1):131-141
  • Immune checkpoint inhibition in patients with brain metastases
    Johanns T, Waqar SN, Morgensztern D
    Ann Transl Med 2016 Oct;4(Suppl 1):S9
  • Consolidation chemotherapy following weekly carboplatin-paclitaxel based chemoradiation for locally advanced non-small cell lung cancer is associated with improved overall and disease-free survival
    Weiner AA, Speirs CK, DeWees TA, Rehman S, Molotievschi A, Velez MA, Mullen D, Fergus S, Trovo M, Baggstrom MQ, Morgensztern D, Govindan R, Waqar SN, Bradley JD, Robinson CG
    Int J Radiat Oncol Biol Phys 2016 Oct 1;96(2S):E441-E442
  • Patterns of care and survival for early versus delayed radiation therapy (RT) in limited-stage small cell lung cancer (LS-SCLC): A review of the National Cancer Data Base
    Robinson CG, Samson P, Bradley JD, Roach MC, DeWees TA, Waqar SN, Baggstrom MQ, Govindan R, Higgins KA, Simone CB 2nd, Grover S, Puri V, Morgensztern D
    Int J Radiat Oncol Biol Phys 2016 Oct 1;96(2S):E436-E437
  • Role for adjuvant chemotherapy in patients with resected small cell lung cancer
    Du L, Waqar SN, Morgensztern D
    J Thorac Dis 2016 Aug;8(8):1891-2
  • Adjuvant chemotherapy for patients with T2N0M0 NSCLC
    Morgensztern D, Du L, Waqar SN, Patel A, Samson P, Devarakonda S, Gao F, Robinson CG, Bradley J, Baggstrom M, Masood A, Govindan R, Puri V
    J Thorac Oncol 2016 Oct;11(10):1729-35
  • Multimodality therapy for NSCLC
    Du L, Waqar SN, Morgensztern D
    Cancer Treat Res 2016;170:151-63
  • Nivolumab and pembrolizumab for non-small cell lung cancer
    Morgensztern D, Herbst RS
    Clin Cancer Res 2016 Aug 1;22(15):3713-7
  • Patterns of care in hilar node-positive (N1) non-small cell lung cancer: A missed treatment opportunity?
    Bott MJ, Patel AP, Verma V, Crabtree TD, Morgensztern D, Robinson CG, Colditz GA, Waqar S, Kreisel D, Krupnick AS, Patterson GA, Broderick S, Meyers BF, Puri V
    J Thorac Cardiovasc Surg 2016 Jun;151(6):1549-1558e2
  • Delayed nausea and vomiting from carboplatin doublet chemotherapy
    Waqar SN, Mann J, Baggstrom MQ, Waqar MA, Chitneni P, Williams K, Gao F, Morgensztern D, Govindan R
    Acta Oncol 2016 Jun;55(6):700-4
  • A phase I trial of temsirolimus and pemetrexed in patients with advanced non-small cell lung cancer
    Waqar SN, Baggstrom MQ, Morgensztern D, Williams K, Rigden C, Govindan R
    Chemotherapy 2016;61(3):144-7
  • Immunogenicity of influenza vaccination in patients with cancer
    Waqar SN, Boehmer L, Morgensztern D, Wang-Gillam A, Sorscher S, Lawrence S, Gao F, Guebert K, Williams K, Govindan R
    Am J Clin Oncol 2015 Dec 14; [Epub ahead of print]
  • Brain metastases at presentation in patients with non-small cell lung cancer
    Waqar SN, Waqar SH, Trinkaus K, Gadea CA, Robinson CG, Bradley J, Watson MA, Puri V, Govindan R, Morgensztern D
    Am J Clin Oncol 2015 Sep 3; [Epub ahead of print]
  • The role of surgical resection in stage IIIa non-small cell lung cancer: a decision and cost-effectiveness analysis
    Samson P, Patel A, Robinson CG, Morgensztern D, Chang SH, Colditz GA, Waqar S, Crabtree TD, Krupnick AS, Kreisel D, Patterson GA, Meyers BF, Puri V
    Ann Thorac Surg 2015 Dec;100(6):2026-2032
  • Multidisciplinary treatment for stage IIIa non-small cell lung cancer: does institution type matter?
    Samson P, Patel A, Crabtree TD, Morgensztern D, Robinson CG, Colditz GA, Waqar S, Kreisel D, Krupnick AS, Patterson GA, Broderick S, Meyers BF, Puri V
    Ann Thorac Surg 2015 Nov;100(5):1773-9
  • EGFR mutations in non-small-cell lung cancer: find, divide, and conquer
    Morgensztern D, Politi K, Herbst RS
    JAMA Oncol 2015 May 1;1(2):146-148
  • Chemotherapy for advanced-stage non-small cell lung cancer
    Du L, Morgensztern D
    Cancer J 2015 Sep-Oct;21(5):366-370
  • Genomic alterations in lung adenocarcinoma
    Devarakonda S, Morgensztern D, Govindan R
    Lancet Oncol 2015 Jul;16(7):e342-51
  • Treatment outcomes in stage I lung cancer: a comparison of surgery and stereotactic body radiation therapy
    Puri V, Crabtree TD, Bell JM, Broderick SR, Morgensztern D, Colditz GA, Kreisel D, Krupnick AS, Patterson GA, Meyers BF, Patel A, Robinson CG
    J Thorac Oncol 2015 Dec;10(12):1776-1784
  • MET mutation associated with responsiveness to crizotinib
    Waqar SN, Morgensztern D, Sehn J
    J Thorac Oncol 2015 May;10(5):e29-31
  • Immunotherapy for non-small cell lung cancer: are we on the cusp of a new era?
    Waqar SN, Morgensztern D
    Expert Rev Clin Immunol 2015 Aug;11(8):871-873
  • Role for surgical resection in the multidisciplinary treatment of stage IIIB non-small cell lung cancer
    Bott MJ, Patel AP, Crabtree TD, Morgensztern D, Robinson CG, Colditz GA, Waqar S, Kreisel D, Krupnicka AS, Patterson GA, Broderick S, Meyers BF, Puri V
    Ann Thorac Surg 2015 Jun;99(6):1921-1928
  • Postoperative radiotherapy for pathologic n2 non-small-cell lung cancer treated with adjuvant chemotherapy: a review of the national cancer data base
    Robinson CG, Patel AP, Bradley JD, DeWees T, Waqar SN, Morgensztern D, Baggstrom MQ, Govindan R, Bell JM, Guthrie TJ, Colditz GA, Crabtree TD, Kreisel D, Krupnick AS, Patterson GA, Meyers BF, Puri V
    J Clin Oncol 2015 Mar 10;33(8):870-6
  • Molecularly targeted therapies in non-small-cell lung cancer annual update 2014
    Morgensztern D, Campo MJ, Dahlberg SE, Doebele RC, Garon E, Gerber DE, Goldberg SB, Hammerman PS, Heist RS, Hensing T, Horn L, Ramalingam SS, Rudin CM, Salgia R, Sequist LV, Shaw AT, Simon GR, Somaiah N, Spigel DR, Wrangle J, Johnson D, Herbst RS, Bunn P, Govindan R
    J Thorac Oncol 2015 Jan;10(1 Suppl 1):S1-S63
  • Clinical next-generation sequencing in patients with non-small cell lung cancer
    Hagemann IS, Devarakonda S, Lockwood CM, Spencer DH, Guebert K, Bredemeyer AJ, Al-Kateb H, Nguyen TT, Duncavage EJ, Cottrell CE, Kulkarni S, Nagarajan R, Seibert K, Baggstrom M, Waqar SN, Pfeifer JD, Morgensztern D, Govindan R
    Cancer 2015 Feb 15;121(4):631-9
  • Central nervous system toxicities of chemotherapeutic agents
    Peddi PF, Peddi S, Santos ES, Morgensztern D
    Expert Rev Anticancer Ther 2014 Jul;14(7):857-863
  • Treating locally advanced disease: an analysis of very large, hilar lymph node positive non-small cell lung cancer using the National Cancer Data Base
    Moreno AC, Morgensztern D, Boffa DJ, Decker RH, Yu JB, Detterbeck FC, Wang Z, Rose MG, Kim AW
    Ann Thorac Surg 2014 Apr;97(4):1149-55
  • National patterns of care and outcomes after combined modality therapy for stage IIIA non-small-cell lung cancer
    Patel AP, Crabtree TD, Bell JM, Guthrie TJ, Robinson CG, Morgensztern D, Colditz GA, Kreisel D, Krupnick AS, Bradley JD, Patterson GA, Meyers BF, Puri V
    J Thorac Oncol 2014 May;9(5):612-21
  • Risk-stratified patients with resectable soft tissue sarcoma benefit from epirubicin-based adjuvant chemotherapy
    Schenone AD, Luo J, Montgomery L, Morgensztern D, Adkins DR, Van Tine BA
    Cancer Med 2014 Jun;3(3):603-12
  • Summary report from the 13th annual Targeted Therapies of the Treatment of Lung Cancer meeting
    Morgensztern D, Govindan R
    Clin Lung Cancer 2014 Jan;15(1):16-20
  • Clinical applications of The Cancer Genome Atlas project (TCGA) for squamous cell lung carcinoma
    Devarakonda S, Morgensztern D, Govindan R
    Oncology (Williston Park) 2013 Sep;27(9):899-906
  • Molecularly targeted therapies in locally advanced non-small-cell lung cancer
    Devarakonda S, Morgensztern D, Govindan R
    Clin Lung Cancer 2013 Sep;14(5):467-72
  • Impact of preoperative radiation on survival of patients with T3N0 >7-cm non-small cell lung cancers treated with anatomic resection using the Surveillance, Epidemiology, and End Results database
    Moreno AC, Morgensztern D, Yu JB, Boffa DJ, Decker RH, Detterbeck FC, Kim AW
    J Surg Res 2013 Sep;184(1):10-8
  • Genomic landscape of squamous cell carcinoma of the lung
    Morgensztern D, Devarakonda S, Govindan R
    Am Soc Clin Oncol Educ Book 2013:348-53
  • Evaluation of novel orthotopic nude mouse models for human small-cell lung cancer
    Isobe T, Onn A, Morgensztern D, Jacoby JJ, Wu W, Shintani T, Itasaka S, Shibuya K, Koo PJ, O'Reilly MS, Herbst RS
    J Thorac Oncol 2013 Feb;8(2):140-6
  • Use of new treatment modalities for non-small cell lung cancer care in the Medicare population
    Vest MT, Herrin J, Soulos PR, Decker RH, Tanoue L, Michaud G, Kim AW, Detterbeck F, Morgensztern D, Gross CP
    Chest 2013 Feb 1;143(2):429-35
  • Prognostic impact of malignant pleural effusion at presentation in patients with metastatic non-small-cell lung cancer
    Morgensztern D, Waqar S, Subramanian J, Trinkaus K, Govindan R
    J Thorac Oncol 2012 Oct;7(10):1485-9
  • Prognostic significance of tumor size in patients with stage III non-small-cell lung cancer: a surveillance, epidemiology, and end results (SEER) survey from 1998 to 2003
    Morgensztern D, Waqar S, Subramanian J, Gao F, Trinkaus K, Govindan R
    J Thorac Oncol 2012 Oct;7(10):1479-84
  • Miscellaneous agents
    Morgensztern D, Herbst RS
    J Thorac Oncol 2012 Dec;7(16 Suppl 5):S390-1
  • Multitargeted tyrosine kinase inhibitors in unselected patients with advanced non-small-cell lung cancer (NSCLC): impressions from MONET (the motesanib NSCLC efficacy and tolerability study)
    Morgensztern D, Herbst RS
    J Clin Oncol 2012 Aug 10;30(23):2805-8
  • Targeting vascular endothelial growth factor in patients with squamous cell lung cancer
    Koo PJ, Morgensztern D, Boyer JL, Herbst RS
    J Clin Oncol 2012 Apr 1;30(10):1137-9
  • Waldenstrom macroglobulinemia: a Surveillance, Epidemiology, and End Results database review from 1988 to 2005
    Sekhar J, Sanfilippo K, Zhang Q, Trinkaus K, Vij R, Morgensztern D
    Leuk Lymphoma 2012 Aug;53(8):1625-6
  • A roundup of articles published in recent months
    Subramanian J, Waqar S, Morgensztern D, Govindan R
    J Thorac Oncol 2012 Mar;7(3):626-8
  • Thoroughness of mediastinal staging in stage IIIA non-small cell lung cancer
    Vest MT, Tanoue L, Soulos PR, Kim AW, Detterbeck F, Morgensztern D, Gross CP
    J Thorac Oncol 2012 Jan;7(1):188-95
  • Recent advances in lung cancer: summary of presentations from the 47 th annual meeting of the American Society of Clinical Oncology (ASCO) 2011
    Subramanian J, Waqar SN, Morgensztern D, Govindan R
    J Thorac Oncol 2012 Jan;7(1):260-5
  • Medullary thyroid cancer in the past, present and future: from bench to bedside
    Desphande H, Morgensztern D, Sosa JA
    Expert Rev Endocrinol Metab 2011;6:585-97
  • A roundup of recently published articles relevant to thoracic oncology
    Morgensztern D, Govindan R
    J Thorac Oncol 2011 Jul;6(7):1295-7
  • Summary of presentations from the 46th annual meeting of the American Society Of Clinical Oncology (2010): focus on developmental therapeutics related to lung cancer
    Morgensztern D, Pennell NA, Subramanian J, Govindan R
    Clin Lung Cancer 2011 Mar;12(2):94-9
  • Phase II trial of S-1 as second-line therapy in patients with advanced non-small cell lung cancer
    Govindan R, Morgensztern D, Kommor MD, Herbst RS, Schaefer P, Gandhi J, Saito K, Zergebel C, Schiller J
    J Thorac Oncol 2011 Apr;6(4):790-5
  • Summary of presentations from the 46th Annual Meeting of the American Society of Clinical Oncology (2010) focus on tumor biology and biomarkers related to lung cancer
    Subramanian J, Corrales L, Soulieres D, Morgensztern D, Govindan R
    J Thorac Oncol 2011 Feb;6(2):399-403
  • Best of the month: A round up of articles published in recent months
    Morgensztern D, Govindan R
    J Thorac Oncol 2011 Jan;6(1):223-6
  • Barriers to enrollment in non-small cell lung cancer therapeutic clinical trials
    Baggstrom MQ, Waqar SN, Sezhiyan AK, Gilstrap E, Gao F, Morgensztern D, Govindan R
    J Thorac Oncol 2011 Jan;6(1):98-102
  • Lack of survival improvement in patients with peripheral T-cell lymphoma: a Surveillance, Epidemiology, and End Results analysis
    Morgensztern D, Walker GR, Koniaris LG, Lossos IS
    Leuk Lymphoma 2011 Feb;52(2):194-204
  • Squamous cell cancer of the head and neck with distant metastasis at presentation
    Kuperman DI, Auethavekiat V, Adkins DR, Nussenbaum B, Collins S, Boonchalermvichian C, Trinkaus K, Chen L, Morgensztern D
    Head Neck 2011 May;33(5):714-8
  • Vaccines and immunotherapy for non-small cell lung cancer
    Morgensztern D, Goodgame B, Govindan R
    J Thorac Oncol 2010 Dec;5(12 Suppl 6):S463-5
  • Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer
    Subramanian J, Morgensztern D, Govindan R
    Clin Lung Cancer 2010 Sep 1;11(5):311-9
  • Review of ongoing clinical trials in non-small cell lung cancer: a status report for 2009 from the ClinicalTrials.gov website
    Subramanian J, Madadi AR, Dandona M, Williams K, Morgensztern D, Govindan R
    J Thorac Oncol 2010 Aug;5(8):1116-9
  • Best of the month: a roundup of articles published in recent months
    Morgensztern D, Govindan R
    J Thorac Oncol 2010 Aug;5(8):1305-7
  • Management of patients with advanced non-small cell lung cancer: role of gefitinib
    Velcheti V, Morgensztern D, Govindan R
    Biologics 2010 May 25;4:83-90
  • High rate and prolonged duration of complete remissions induced by rituximab, methotrexate, doxorubicin, cyclophosphamide, vincristine, ifosfamide, etoposide, cytarabine, and thalidomide (R-MACLO-IVAM-T), a modification of the National Cancer Institute 89-C-41 regimen, in patients with newly diagnosed mantle cell lymphoma
    Lossos IS, Hosein PJ, Morgensztern D, Coleman F, Escalon MP, Byrne GE Jr, Rosenblatt JD, Walker GR
    Leuk Lymphoma 2010 Mar;51(3):406-14
  • Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database survey
    Morgensztern D, Ng SH, Gao F, Govindan R
    J Thorac Oncol 2010 Jan;5(1):29-33
  • Distinctive characteristics of non-small cell lung cancer (NSCLC) in the young: a surveillance, epidemiology, and end results (SEER) analysis
    Subramanian J, Morgensztern D, Goodgame B, Baggstrom MQ, Gao F, Piccirillo J, Govindan R
    J Thorac Oncol 2010 Jan;5(1):23-8
  • Primary plasma cell leukemia: a Surveillance, Epidemiology, and End Results database analysis between 1973 and 2004
    Ramsingh G, Mehan P, Luo J, Vij R, Morgensztern D
    Cancer 2009 Dec 15;115(24):5734-9
  • Novel cytotoxic agents
    Morgensztern D, Belani CP
    J Thorac Oncol 2009 Nov;4(11 Suppl 3):S1082-3
  • Improving survival for stage IV non-small cell lung cancer: a surveillance, epidemiology, and end results survey from 1990 to 2005
    Morgensztern D, Waqar S, Subramanian J, Gao F, Govindan R
    J Thorac Oncol 2009 Dec;4(12):1524-9
  • A phase I study of pegylated liposomal doxorubicin and irinotecan in patients with solid tumors
    Morgensztern D, Baggstrom MQ, Pillot G, Tan B, Fracasso P, Suresh R, Wildi J, Govindan R
    Chemotherapy 2009;55(6):441-5
  • Prognostic factors influencing survival in solitary plasmacytoma
    Ramsingh G, Mehan P, Morgensztern D, Luo J, Vij R
    Br J Haematol 2009 May;145(4):540-2
  • Pulmonary marginal zone lymphoma: a single centre experience and review of the SEER database
    Stefanovic A, Morgensztern D, Fong T, Lossos IS
    Leuk Lymphoma 2008 Jul;49(7):1311-20
  • Adjuvant chemotherapy for lung cancer: cisplatin doublets only?
    Morgensztern D, Govindan R
    J Natl Compr Canc Netw 2008 Mar;6(3):277-84
  • EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer
    Fong T, Morgensztern D, Govindan R
    J Thorac Oncol 2008 Mar;3(3):303-10
  • The effect of FDG-PET on the stage distribution of non-small cell lung cancer
    Morgensztern D, Goodgame B, Baggstrom MQ, Gao F, Govindan R
    J Thorac Oncol 2008 Feb;3(2):135-9
  • A Phase II trial of split, low-dose docetaxel and low-dose capecitabine: a tolerable and efficacious regimen in the first-line treatment of patients with HER2/neu-negative metastatic breast cancer
    Silva O, Lopes G, Morgensztern D, Lobo C, Doliny P, Santos E, Abdullah S, Gautam U, Reis I, Welsh C, Slingerland J, Hurley J, Gluck S
    Clin Breast Cancer 2008 Apr;8(2):162-7
  • Augmentation of anti-tumor responses of adoptively transferred CD8+T cells in the lymphopenic setting by HSV amplicon transduction
    Nechushtan H, Pham D, Zhang Y, Morgensztern D, Yi KH, Shin SU, Federoff HJ, Bowers WJ, Tolba KA, Rosenblatt JD
    Cancer Immunol Immunother 2008 May;57(5):663-75
  • A phase II study of topotecan and docetaxel in patients with sensitive relapse small cell lung cancer
    Morgensztern D, Perry MC, Govindan R
    Acta Oncol 2008;47(1):152-3
  • Treatment of patients excluded from Eastern Cooperative Oncology Group 4599 and AVAiL studies: focus on brain metastasis and squamous histology
    Morgensztern D, Govindan R
    Clin Lung Cancer 2008 Mar;9 Suppl 2:S57-61
  • Is there a role for cetuximab in non small cell lung cancer?
    Morgensztern D, Govindan R
    Clin Cancer Res 2007 Aug 1;13(15 Pt 2):s4602-5
  • Rituximab for treatment of chemoimmunotherapy naive marginal zone lymphoma
    Lossos IS, Morgensztern D, Blaya M, Alencar A, Pereira D, Rosenblatt J
    Leuk Lymphoma 2007 Aug;48(8):1630-2
  • Second-line therapy for esophageal cancer
    Martin MG, Govindan R, Morgensztern D
    Expert Rev Anticancer Ther 2007 Jun;7(6):871-6
  • Gene expression profiling in diffuse large B-cell lymphoma
    Morgensztern D, Martin MG, Lossos IS
    Leuk Lymphoma 2007 Apr;48(4):669-82
  • Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database
    Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, Spitznagel EL, Piccirillo J
    J Clin Oncol 2006 Oct 1;24(28):4539-44
  • Clinical trials of antiangiogenic therapy in non-small cell lung cancer: focus on bevacizumab and ZD6474
    Morgensztern D, Govindan R
    Expert Rev Anticancer Ther 2006 Apr;6(4):545-51
  • Prognostic biomarkers in diffuse large B-cell lymphoma
    Lossos IS, Morgensztern D
    J Clin Oncol 2006 Feb 20;24(6):995-1007
  • PI3K/Akt/mTOR pathway as a target for cancer therapy
    Morgensztern D, McLeod HL
    Anticancer Drugs 2005 Sep;16(8):797-803
  • Molecular prognostic factors in diffuse large B-cell lymphoma
    Morgensztern D, Lossos IS
    Curr Treat Options Oncol 2005 Jul;6(4):269-77
  • Combination of imatinib and cytarabine for the treatment of Philadelphia chromosome positive acute lymphoblastic leukemia
    Morgensztern D, Rosado MF, Raez LE, Santos ES, Cassileth PA
    Leuk Lymphoma 2005 Feb;46(2):297-8
  • Primary lymphoblastic B-cell lymphoma of the cranial dura mater: a case report and review of the literature
    Abdullah S, Morgensztern D, Rosado MF, Lossos IS
    Leuk Lymphoma 2005 Nov;46(11):1651-7
  • Prevalence of hepatitis C infection in patients with non-Hodgkin's lymphoma in South Florida and review of the literature
    Morgensztern D, Rosado M, Silva O, Santos E, Abdullah S, Goodman M, Hamilton-Nelson K, Rosenblatt J, Lossos I
    Leuk Lymphoma 2004 Dec;45(12):2459-64
  • Non-Hodgkin's lymphoma in the microarray era
    Lossos IS, Morgensztern D
    Clin Lymphoma 2004 Sep;5(2):128-9
  • Chronic lymphocytic leukemia-associated nephrotic syndrome caused by focal segmental glomerulosclerosis
    Rosado MF, Morgensztern D, Abdullah S, Ruiz P, Lossos IS
    Am J Hematol 2004 Oct;77(2):205-6
  • Somatostatin receptor scintigraphy in MALT lymphoma of the lacrimal gland treated with rituximab
    Morgensztern D, Rosado MF, Serafini AN, Lossos IS
    Leuk Lymphoma 2004 Jun;45(6):1275-8
  • Primary diffuse large cell lymphoma of the mandible
    Rosado MF, Morgensztern D, Peleg M, Lossos IS
    Leuk Lymphoma 2004 May;45(5):1049-53
  • Heparin-induced thrombocytopenia presenting with thrombosis of multiple saphenous vein grafts and myocardial infarction
    Ayala E, Rosado MF, Morgensztern D, Kharfan-Dabaja MA, Byrnes JJ
    Am J Hematol 2004 Aug;76(4):383-5
  • Primary hepatic non-Hodgkin's lymphomas: case report and review of the literature
    Santos ES, Raez LE, Salvatierra J, Morgensztern D, Shanmugan N, Neff GW
    Am J Gastroenterol 2003 Dec;98(12):2789-93
  • Acute graft-versus-host disease (aGVHD) presenting with an acquired lupus anticoagulant
    Kharfan-Dabaja MA, Morgensztern D, Santos E, Goodman M, Fernandez HF
    Bone Marrow Transplant 2003 Jan;31(2):129-31
  • Interleukin-2 and rituximab in lymphoma: rationale and current trials
    Morgensztern D, Wolin M, Rosenblatt JD
    Biological Therapy of Lymphoma 2002;5:12-16
  • Warm-antibody autoimmune hemolytic anemia developing after thrombotic thrombocytopenic purpura
    Morgensztern D, Kharfan-Dabaja MA, Tsai HM, Lian EC
    Acta Haematol 2002;108(3):154-6
  • Radiation recall dermatitis induced by methotrexate in a patient with Hodgkin's disease
    Kharfan Dabaja MA, Morgensztern D, Markoe AM, Bartlett-Pandite L
    Am J Clin Oncol 2000 Oct;23(5):531-3